Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 The present document updates the 2018 research framework in response to several recent developments.
• 2 Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD.
• 3 The present document is consistent with this principle.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: